Melanoma
Conference Coverage
TLR9 agonist may overcome resistance to anti–PD-1 therapy in melanoma
NATIONAL HARBOR, MD. – CMP-001 plus pembrolizumab produced durable responses in patients who had progressed on prior...
Conference Coverage
In Oregon, ‘war on melanoma’ takes flight
LAS VEGAS – Research project hopes to shrink melanoma mortality by emphasizing education, screening.
Conference Coverage
Melanoma incidence continues to increase, yet mortality stabilizing
LAS VEGAS –Targeted screening efforts that stratify by risk factors and by age “makes screening more efficient and more cost effective.”
From the Journals
Case-control study IDs several novel risk factors of post-HCT melanoma
Latest News
Levothyroxine dose for checkpoint inhibitor thyrotoxicity may be too high
CHICAGO – Dosing need not be automatically boosted when starting checkpoint inhibitor therapy.
Sponsored Supplement
Metastatic Melanoma: The Role of Immuno-Oncology in the Evolving Treatment Landscape
From the Journals
MMS linked with better survival in early-stage melanoma
Patients who underwent Mohs micrographic surgery had moderately better survival, compared with those who were treated with wide margin excision....
From the Journals
Nivolumab-ipilimumab nets long-term survival in advanced melanoma
An update of CheckMate 067 finds that with combination nivolumab and ipilimumab therapy, 52% of patients were alive at 5 years, and the large...
From the Journals
Cancer burden: Multiple metrics needed to clarify the big picture
A cancer’s so-called epidemiologic signature – the composite pattern of incidence, mortality, and metastatic incidence – helps sort out the...
From the Journals
Prior antibiotic use lowers checkpoint inhibitor response and survival
Patients who take antibiotics in the 30 days prior to starting checkpoint inhibitor therapy for cancer have significantly lower overall survival...
From the Journals
Severe lipodystrophy linked to pembrolizumab
A 47-year-old woman developed severe lipodystrophy after receiving pembrolizumab to treat metastatic melanoma.
From the Journals
Dabrafenib plus trametinib yields long-term benefit in melanoma patients
A long-term survival benefit was seen in about a third of patients with metastatic or unresectable melanoma who underwent first-line treatment...